Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab

Annals of the Rheumatic Diseases

Volumn 71, Issue 1, 2012, Pages 75-79

  Hoyer, Bimba F ^a,b   Mumtaz, Imtiaz M ^a,b   Loddenkemper, Konstanze ^a   Bruns, Anne ^a   Sengler, Claudia ^a   Hermann, Kay Geert ^a   Maza, Sofiane ^a   Keitzer, Rolf ^a   Burmester, Gerd Rüdiger ^a   Buttgereit, Frank ^a   Radbruch, Andreas ^b   Hiepe, Falk ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Leibniz Institute   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; CD20 ANTIBODY; CD27 ANTIGEN; RITUXIMAB;

ADOLESCENT; ADULT; AORTA ARCH SYNDROME; ARTICLE; B LYMPHOCYTE; CELL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; HUMAN CELL; MALE; PLASMA CELL; PRIORITY JOURNAL; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTE SUBSETS; DRUG EVALUATION; FEMALE; HOMEOSTASIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TAKAYASU ARTERITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82955235599     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.153007     Document Type: Article

References (20)

1. Johnston SL, Lock RJ, Gompels MM. Takayasu arteritis: a review. J Clin Pathol 2002;55:481-6. (Pubitemid 34779296)
2. Molloy ES, Langford CA, Clark TM, et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008;67:1567-9.
3. Arnaud L, Kahn JE, Girszyn N, et al. Takayasu's arteritis: an update on physiopathology. Eur J Intern Med 2006;17:241-6. (Pubitemid 43817514)
4. Sima D, Thiele B, Turowski A, et al. Anti-endothelial antibodies in Takayasu arteritis. Arthritis Rheum 1994;37:441-3. (Pubitemid 24093641)
5. Inder SJ, Bobryshev YV, Cherian SM, et al. Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg 2000;8:141-8. (Pubitemid 30110714)
6. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129-34. (Pubitemid 20273298)
7. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994;120:919-29. (Pubitemid 24179154)
8. Moriwaki R, Noda M, Yajima M, et al. Clinical manifestations of Takayasu arteritis in India and Japan: new classification of angiographic findings. Angiology 1997;48:369-79. (Pubitemid 27255010)
9. Jacobi AM, Mei H, Hoyer BF, et al. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis 2010;69:305-8.
10. Manz RA, Löhning M, Cassese G, et al. Survival of long-lived plasma cells is independent of antigen. Int Immunol 1998;10:1703-11. (Pubitemid 28502384)
11. Odendahl M, Jacobi A, Hansen A, et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000; 165:5970-9.
12. Nishimoto N, Nakahara H, Yoshio-Hoshino N, et al. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008;58:1197-200. (Pubitemid 351564023)
13. Nishino Y, Tamai M, Kawakami A, et al. Serum levels of BAFF for assessing the disease activity of Takayasu arteritis. Clin Exp Rheumatol 2010;28(1 Suppl 57):14-7.
14. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebocontrolled, phase 3 trial. Lancet 2011;377:721-31.
15. Robles M, Reyes PA. Takayasu's arteritis in Mexico: a clinical review of 44 consecutive cases. Clin Exp Rheumatol 1994;12:381-8. (Pubitemid 24244027)
16. Wang H, Ma J, Wu Q, et al. Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg 2011;53:174-80.
17. Galarza C, Valencia D, Tobón GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 2008;34:124-8.
18. Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005;64:1099-100. (Pubitemid 40909539)
19. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001;1:147-53. (Pubitemid 33741968)
20. Hiepe F, Dörner T, Hauser AE, et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011;7:170-8.